世界の拡張型心筋症治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Dilated Cardiomyopathy Therapeutic Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4136 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、拡張型心筋症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アルドステロン拮抗薬、アンジオテンシン変換酵素（ACE）阻害薬、アンジオテンシンII受容体拮抗薬（ARB）、ベータ遮断薬）、用途別市場規模（病院、学術機関）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・拡張型心筋症治療薬の市場動向 ・企業の競争状況、市場シェア ・拡張型心筋症治療薬の種類別市場規模と予測2016-2027（アルドステロン拮抗薬、アンジオテンシン変換酵素（ACE）阻害薬、アンジオテンシンII受容体拮抗薬（ARB）、ベータ遮断薬） ・拡張型心筋症治療薬の用途別市場規模と予測2016-2027（病院、学術機関） ・拡張型心筋症治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・拡張型心筋症治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・拡張型心筋症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・拡張型心筋症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・拡張型心筋症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Array BioPharma, Inc.、AstraZeneca plc.、Celladon Corporation、GlaxoSmithKline plc、Janssen Pharmaceuticals, Inc. (J&J)、Merck & Co., Inc.、Novartis International AG、Pfizer, Inc.、Sanofi S.A.、Teva Pharmaceutical Industries Ltd.、Vericel Corporation） ・結論

Dilated cardiomyopathy (DCM) is characterized by LV (left ventricular) or biventricular systolic dysfunction and dilation, not explained by abnormal loading conditions or coronary artery disease.

Market Analysis and Insights: Global Dilated Cardiomyopathy Therapeutic Market
The global Dilated Cardiomyopathy Therapeutic market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Dilated Cardiomyopathy Therapeutic market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Dilated Cardiomyopathy Therapeutic market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Dilated Cardiomyopathy Therapeutic market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Dilated Cardiomyopathy Therapeutic market.

Global Dilated Cardiomyopathy Therapeutic Scope and Market Size
Dilated Cardiomyopathy Therapeutic market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Dilated Cardiomyopathy Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Aldosterone antagonists
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin II receptor blockers (ARBs)
Beta-blockers

Segment by Application
Hospitals
Academic Institutions

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Array BioPharma, Inc.
AstraZeneca plc.
Celladon Corporation
GlaxoSmithKline plc
Janssen Pharmaceuticals, Inc. (J&J)
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Vericel Corporation

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dilated Cardiomyopathy Therapeutic Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Aldosterone antagonists
1.2.3 Angiotensin-converting enzyme (ACE) inhibitors
1.2.4 Angiotensin II receptor blockers (ARBs)
1.2.5 Beta-blockers
1.3 Market by Application
1.3.1 Global Dilated Cardiomyopathy Therapeutic Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Academic Institutions
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Dilated Cardiomyopathy Therapeutic Market Perspective (2016-2027)
2.2 Dilated Cardiomyopathy Therapeutic Growth Trends by Regions
2.2.1 Dilated Cardiomyopathy Therapeutic Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Dilated Cardiomyopathy Therapeutic Historic Market Share by Regions (2016-2021)
2.2.3 Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Regions (2022-2027)
2.3 Dilated Cardiomyopathy Therapeutic Industry Dynamic
2.3.1 Dilated Cardiomyopathy Therapeutic Market Trends
2.3.2 Dilated Cardiomyopathy Therapeutic Market Drivers
2.3.3 Dilated Cardiomyopathy Therapeutic Market Challenges
2.3.4 Dilated Cardiomyopathy Therapeutic Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Dilated Cardiomyopathy Therapeutic Players by Revenue
3.1.1 Global Top Dilated Cardiomyopathy Therapeutic Players by Revenue (2016-2021)
3.1.2 Global Dilated Cardiomyopathy Therapeutic Revenue Market Share by Players (2016-2021)
3.2 Global Dilated Cardiomyopathy Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Dilated Cardiomyopathy Therapeutic Revenue
3.4 Global Dilated Cardiomyopathy Therapeutic Market Concentration Ratio
3.4.1 Global Dilated Cardiomyopathy Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dilated Cardiomyopathy Therapeutic Revenue in 2020
3.5 Dilated Cardiomyopathy Therapeutic Key Players Head office and Area Served
3.6 Key Players Dilated Cardiomyopathy Therapeutic Product Solution and Service
3.7 Date of Enter into Dilated Cardiomyopathy Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Dilated Cardiomyopathy Therapeutic Breakdown Data by Type
4.1 Global Dilated Cardiomyopathy Therapeutic Historic Market Size by Type (2016-2021)
4.2 Global Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Type (2022-2027)

5 Dilated Cardiomyopathy Therapeutic Breakdown Data by Application
5.1 Global Dilated Cardiomyopathy Therapeutic Historic Market Size by Application (2016-2021)
5.2 Global Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Dilated Cardiomyopathy Therapeutic Market Size (2016-2027)
6.2 North America Dilated Cardiomyopathy Therapeutic Market Size by Type
6.2.1 North America Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2021)
6.2.2 North America Dilated Cardiomyopathy Therapeutic Market Size by Type (2022-2027)
6.2.3 North America Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2027)
6.3 North America Dilated Cardiomyopathy Therapeutic Market Size by Application
6.3.1 North America Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2021)
6.3.2 North America Dilated Cardiomyopathy Therapeutic Market Size by Application (2022-2027)
6.3.3 North America Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2027)
6.4 North America Dilated Cardiomyopathy Therapeutic Market Size by Country
6.4.1 North America Dilated Cardiomyopathy Therapeutic Market Size by Country (2016-2021)
6.4.2 North America Dilated Cardiomyopathy Therapeutic Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Dilated Cardiomyopathy Therapeutic Market Size (2016-2027)
7.2 Europe Dilated Cardiomyopathy Therapeutic Market Size by Type
7.2.1 Europe Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2021)
7.2.2 Europe Dilated Cardiomyopathy Therapeutic Market Size by Type (2022-2027)
7.2.3 Europe Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2027)
7.3 Europe Dilated Cardiomyopathy Therapeutic Market Size by Application
7.3.1 Europe Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2021)
7.3.2 Europe Dilated Cardiomyopathy Therapeutic Market Size by Application (2022-2027)
7.3.3 Europe Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2027)
7.4 Europe Dilated Cardiomyopathy Therapeutic Market Size by Country
7.4.1 Europe Dilated Cardiomyopathy Therapeutic Market Size by Country (2016-2021)
7.4.2 Europe Dilated Cardiomyopathy Therapeutic Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size (2016-2027)
8.2 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Type
8.2.1 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2027)
8.3 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Application
8.3.1 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2027)
8.4 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Region
8.4.1 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Dilated Cardiomyopathy Therapeutic Market Size (2016-2027)
9.2 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Type
9.2.1 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2021)
9.2.2 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Type (2022-2027)
9.2.3 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2027)
9.3 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Application
9.3.1 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2021)
9.3.2 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Application (2022-2027)
9.3.3 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2027)
9.4 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Country
9.4.1 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Country (2016-2021)
9.4.2 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size (2016-2027)
10.2 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Type
10.2.1 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2027)
10.3 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Application
10.3.1 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2027)
10.4 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Country
10.4.1 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Array BioPharma, Inc.
11.1.1 Array BioPharma, Inc. Company Details
11.1.2 Array BioPharma, Inc. Business Overview
11.1.3 Array BioPharma, Inc. Dilated Cardiomyopathy Therapeutic Introduction
11.1.4 Array BioPharma, Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
11.1.5 Array BioPharma, Inc. Recent Development
11.2 AstraZeneca plc.
11.2.1 AstraZeneca plc. Company Details
11.2.2 AstraZeneca plc. Business Overview
11.2.3 AstraZeneca plc. Dilated Cardiomyopathy Therapeutic Introduction
11.2.4 AstraZeneca plc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
11.2.5 AstraZeneca plc. Recent Development
11.3 Celladon Corporation
11.3.1 Celladon Corporation Company Details
11.3.2 Celladon Corporation Business Overview
11.3.3 Celladon Corporation Dilated Cardiomyopathy Therapeutic Introduction
11.3.4 Celladon Corporation Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
11.3.5 Celladon Corporation Recent Development
11.4 GlaxoSmithKline plc
11.4.1 GlaxoSmithKline plc Company Details
11.4.2 GlaxoSmithKline plc Business Overview
11.4.3 GlaxoSmithKline plc Dilated Cardiomyopathy Therapeutic Introduction
11.4.4 GlaxoSmithKline plc Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
11.4.5 GlaxoSmithKline plc Recent Development
11.5 Janssen Pharmaceuticals, Inc. (J&J)
11.5.1 Janssen Pharmaceuticals, Inc. (J&J) Company Details
11.5.2 Janssen Pharmaceuticals, Inc. (J&J) Business Overview
11.5.3 Janssen Pharmaceuticals, Inc. (J&J) Dilated Cardiomyopathy Therapeutic Introduction
11.5.4 Janssen Pharmaceuticals, Inc. (J&J) Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
11.5.5 Janssen Pharmaceuticals, Inc. (J&J) Recent Development
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Details
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Dilated Cardiomyopathy Therapeutic Introduction
11.6.4 Merck & Co., Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
11.6.5 Merck & Co., Inc. Recent Development
11.7 Novartis International AG
11.7.1 Novartis International AG Company Details
11.7.2 Novartis International AG Business Overview
11.7.3 Novartis International AG Dilated Cardiomyopathy Therapeutic Introduction
11.7.4 Novartis International AG Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
11.7.5 Novartis International AG Recent Development
11.8 Pfizer, Inc.
11.8.1 Pfizer, Inc. Company Details
11.8.2 Pfizer, Inc. Business Overview
11.8.3 Pfizer, Inc. Dilated Cardiomyopathy Therapeutic Introduction
11.8.4 Pfizer, Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
11.8.5 Pfizer, Inc. Recent Development
11.9 Sanofi S.A.
11.9.1 Sanofi S.A. Company Details
11.9.2 Sanofi S.A. Business Overview
11.9.3 Sanofi S.A. Dilated Cardiomyopathy Therapeutic Introduction
11.9.4 Sanofi S.A. Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
11.9.5 Sanofi S.A. Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Details
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Dilated Cardiomyopathy Therapeutic Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.11 Vericel Corporation
11.11.1 Vericel Corporation Company Details
11.11.2 Vericel Corporation Business Overview
11.11.3 Vericel Corporation Dilated Cardiomyopathy Therapeutic Introduction
11.11.4 Vericel Corporation Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
11.11.5 Vericel Corporation Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Dilated Cardiomyopathy Therapeutic Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Aldosterone antagonists
Table 3. Key Players of Angiotensin-converting enzyme (ACE) inhibitors
Table 4. Key Players of Angiotensin II receptor blockers (ARBs)
Table 5. Key Players of Beta-blockers
Table 6. Global Dilated Cardiomyopathy Therapeutic Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Dilated Cardiomyopathy Therapeutic Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Dilated Cardiomyopathy Therapeutic Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Dilated Cardiomyopathy Therapeutic Market Share by Regions (2016-2021)
Table 10. Global Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Dilated Cardiomyopathy Therapeutic Market Share by Regions (2022-2027)
Table 12. Dilated Cardiomyopathy Therapeutic Market Trends
Table 13. Dilated Cardiomyopathy Therapeutic Market Drivers
Table 14. Dilated Cardiomyopathy Therapeutic Market Challenges
Table 15. Dilated Cardiomyopathy Therapeutic Market Restraints
Table 16. Global Dilated Cardiomyopathy Therapeutic Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Dilated Cardiomyopathy Therapeutic Market Share by Players (2016-2021)
Table 18. Global Top Dilated Cardiomyopathy Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dilated Cardiomyopathy Therapeutic as of 2020)
Table 19. Ranking of Global Top Dilated Cardiomyopathy Therapeutic Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Dilated Cardiomyopathy Therapeutic Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Dilated Cardiomyopathy Therapeutic Product Solution and Service
Table 23. Date of Enter into Dilated Cardiomyopathy Therapeutic Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Dilated Cardiomyopathy Therapeutic Revenue Market Share by Type (2016-2021)
Table 27. Global Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Dilated Cardiomyopathy Therapeutic Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Dilated Cardiomyopathy Therapeutic Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Dilated Cardiomyopathy Therapeutic Revenue Market Share by Application (2016-2021)
Table 31. Global Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Dilated Cardiomyopathy Therapeutic Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Dilated Cardiomyopathy Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Dilated Cardiomyopathy Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Dilated Cardiomyopathy Therapeutic Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Dilated Cardiomyopathy Therapeutic Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Dilated Cardiomyopathy Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Dilated Cardiomyopathy Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Dilated Cardiomyopathy Therapeutic Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Dilated Cardiomyopathy Therapeutic Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Dilated Cardiomyopathy Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Dilated Cardiomyopathy Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Dilated Cardiomyopathy Therapeutic Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Dilated Cardiomyopathy Therapeutic Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Country (2022-2027) & (US$ Million)
Table 63. Array BioPharma, Inc. Company Details
Table 64. Array BioPharma, Inc. Business Overview
Table 65. Array BioPharma, Inc. Dilated Cardiomyopathy Therapeutic Product
Table 66. Array BioPharma, Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021) & (US$ Million)
Table 67. Array BioPharma, Inc. Recent Development
Table 68. AstraZeneca plc. Company Details
Table 69. AstraZeneca plc. Business Overview
Table 70. AstraZeneca plc. Dilated Cardiomyopathy Therapeutic Product
Table 71. AstraZeneca plc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021) & (US$ Million)
Table 72. AstraZeneca plc. Recent Development
Table 73. Celladon Corporation Company Details
Table 74. Celladon Corporation Business Overview
Table 75. Celladon Corporation Dilated Cardiomyopathy Therapeutic Product
Table 76. Celladon Corporation Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021) & (US$ Million)
Table 77. Celladon Corporation Recent Development
Table 78. GlaxoSmithKline plc Company Details
Table 79. GlaxoSmithKline plc Business Overview
Table 80. GlaxoSmithKline plc Dilated Cardiomyopathy Therapeutic Product
Table 81. GlaxoSmithKline plc Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021) & (US$ Million)
Table 82. GlaxoSmithKline plc Recent Development
Table 83. Janssen Pharmaceuticals, Inc. (J&J) Company Details
Table 84. Janssen Pharmaceuticals, Inc. (J&J) Business Overview
Table 85. Janssen Pharmaceuticals, Inc. (J&J) Dilated Cardiomyopathy Therapeutic Product
Table 86. Janssen Pharmaceuticals, Inc. (J&J) Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021) & (US$ Million)
Table 87. Janssen Pharmaceuticals, Inc. (J&J) Recent Development
Table 88. Merck & Co., Inc. Company Details
Table 89. Merck & Co., Inc. Business Overview
Table 90. Merck & Co., Inc. Dilated Cardiomyopathy Therapeutic Product
Table 91. Merck & Co., Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021) & (US$ Million)
Table 92. Merck & Co., Inc. Recent Development
Table 93. Novartis International AG Company Details
Table 94. Novartis International AG Business Overview
Table 95. Novartis International AG Dilated Cardiomyopathy Therapeutic Product
Table 96. Novartis International AG Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021) & (US$ Million)
Table 97. Novartis International AG Recent Development
Table 98. Pfizer, Inc. Company Details
Table 99. Pfizer, Inc. Business Overview
Table 100. Pfizer, Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021) & (US$ Million)
Table 101. Pfizer, Inc. Recent Development
Table 102. Sanofi S.A. Company Details
Table 103. Sanofi S.A. Business Overview
Table 104. Sanofi S.A. Dilated Cardiomyopathy Therapeutic Product
Table 105. Sanofi S.A. Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021) & (US$ Million)
Table 106. Sanofi S.A. Recent Development
Table 107. Teva Pharmaceutical Industries Ltd. Company Details
Table 108. Teva Pharmaceutical Industries Ltd. Business Overview
Table 109. Teva Pharmaceutical Industries Ltd. Dilated Cardiomyopathy Therapeutic Product
Table 110. Teva Pharmaceutical Industries Ltd. Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021) & (US$ Million)
Table 111. Teva Pharmaceutical Industries Ltd. Recent Development
Table 112. Vericel Corporation Company Details
Table 113. Vericel Corporation Business Overview
Table 114. Vericel Corporation Dilated Cardiomyopathy Therapeutic Product
Table 115. Vericel Corporation Revenue in Dilated Cardiomyopathy Therapeutic Business (2016-2021) & (US$ Million)
Table 116. Vericel Corporation Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Dilated Cardiomyopathy Therapeutic Market Share by Type: 2020 VS 2027
Figure 2. Aldosterone antagonists Features
Figure 3. Angiotensin-converting enzyme (ACE) inhibitors Features
Figure 4. Angiotensin II receptor blockers (ARBs) Features
Figure 5. Beta-blockers Features
Figure 6. Global Dilated Cardiomyopathy Therapeutic Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Academic Institutions Case Studies
Figure 9. Dilated Cardiomyopathy Therapeutic Report Years Considered
Figure 10. Global Dilated Cardiomyopathy Therapeutic Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Dilated Cardiomyopathy Therapeutic Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Dilated Cardiomyopathy Therapeutic Market Share by Regions: 2020 VS 2027
Figure 13. Global Dilated Cardiomyopathy Therapeutic Market Share by Regions (2022-2027)
Figure 14. Global Dilated Cardiomyopathy Therapeutic Market Share by Players in 2020
Figure 15. Global Top Dilated Cardiomyopathy Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dilated Cardiomyopathy Therapeutic as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Dilated Cardiomyopathy Therapeutic Revenue in 2020
Figure 17. Global Dilated Cardiomyopathy Therapeutic Revenue Market Share by Type (2016-2021)
Figure 18. Global Dilated Cardiomyopathy Therapeutic Revenue Market Share by Type (2022-2027)
Figure 19. North America Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Dilated Cardiomyopathy Therapeutic Market Share by Type (2016-2027)
Figure 21. North America Dilated Cardiomyopathy Therapeutic Market Share by Application (2016-2027)
Figure 22. North America Dilated Cardiomyopathy Therapeutic Market Share by Country (2016-2027)
Figure 23. United States Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Dilated Cardiomyopathy Therapeutic Market Share by Type (2016-2027)
Figure 27. Europe Dilated Cardiomyopathy Therapeutic Market Share by Application (2016-2027)
Figure 28. Europe Dilated Cardiomyopathy Therapeutic Market Share by Country (2016-2027)
Figure 29. Germany Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Share by Region (2016-2027)
Figure 39. China Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Dilated Cardiomyopathy Therapeutic Market Share by Type (2016-2027)
Figure 47. Latin America Dilated Cardiomyopathy Therapeutic Market Share by Application (2016-2027)
Figure 48. Latin America Dilated Cardiomyopathy Therapeutic Market Share by Country (2016-2027)
Figure 49. Mexico Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Share by Country (2016-2027)
Figure 55. Turkey Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Array BioPharma, Inc. Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
Figure 59. AstraZeneca plc. Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
Figure 60. Celladon Corporation Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
Figure 61. GlaxoSmithKline plc Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
Figure 62. Janssen Pharmaceuticals, Inc. (J&J) Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
Figure 63. Merck & Co., Inc. Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
Figure 64. Novartis International AG Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
Figure 65. Pfizer, Inc. Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
Figure 66. Sanofi S.A. Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
Figure 67. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
Figure 68. Vericel Corporation Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---